Led · Equity · Jun 2026

OliX develops RNAi therapeutics using its OASIS (OliX Advanced Small Interfering RNA System) platform designed to enhance gene-silencing efficiency and enable tissue-specific delivery. Using OASIS, the company is advancing programs for indications including hair loss, age-related macular degeneration, hypertrophic scars, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and cardiometabolic disorders. Under its “OliX 2.0 Roadmap,” the company is also developing next-generation delivery technologies targeting the central nervous system and adipose tissue while expanding its pipeline of RNAi-based therapies. The recent financing with BOLD and Weiss is intended to accelerate these development programs and strengthen research capabilities. The partnership with L’Oréal via BOLD is positioned as strategic, combining OliX’s siRNA platform with L’Oréal’s expertise in biology, tech, and formulation. OliX has framed the investment as validation of its technological competitiveness and growth potential.

Participated · Series A · May 2026

Launched in 2020, CHOSEN develops dermatologist-designed topical formulations and nutraceuticals addressing pigmentation, skin texture, contour and hair aging. It operates a clinic-to-consumer model that integrates a B2B network of dermatologists with a direct-to-consumer platform, and reports insights from over 150,000 consultations. The company offers around 58 SKUs across doctor-led and D2C segments and its products are prescribed in more than 2,000 clinics nationwide. CHOSEN’s online channel serves customers across India, with nearly 95% of digital sales on its own platform and roughly 70% of revenue driven by repeat customers, primarily women aged 30–50. The company is preparing to expand into global skin-of-color markets in Latin America and East Asia and competes with brands such as Avène, Heliocare, Cetaphil, Sebamed, Shiseido and Dr. Sturm.

Participated · Equity · Mar 2026

KeyCare is a Chicago-based national virtual care organization built on the Epic electronic health record platform. Its technology integrates directly into existing clinical workflows and data infrastructure, enabling health systems to offer virtual visits that are coordinated with in-person care. By embedding into Epic, KeyCare helps providers maintain continuity of records, scheduling, and billing while giving patients a seamless telehealth experience. The company focuses on improving patient and clinician satisfaction through streamlined virtual encounters and robust data sharing. With new capital, KeyCare plans to deepen its investment in AI-enabled capabilities, enhance its platform features, and scale operational capacity to meet rising demand from health-system partners. To date, the company has raised more than $55 million.

Participated · Equity · Feb 2026

Evergreen Select, formerly known as Omeat, develops a cultivated beef platform that aims to deliver fresh, 100% beef without antibiotics, GMOs, or artificial inputs. The company positions its technology as an infrastructure solution that stabilizes supply chains by ensuring consistent quality, taste, texture, and pricing. Rather than targeting the consumer directly, Evergreen pursues a partnership-driven, B2B go-to-market strategy, collaborating with meat distributors in the United States and Singapore to launch blended ground-beef products. Management states that the firm is well advanced in regulatory reviews in both regions and will use new funds to complete due diligence and secure approvals in the near term. Evergreen’s cultivated beef is intended to integrate seamlessly into existing meat-production workflows, helping partners mitigate price volatility and supply shocks. To date, the company has raised more than $55 million to validate and scale its cost-competitive platform, underscoring investor confidence despite a constrained fundraising climate.

Led · Equity · Feb 2026

Evergreen Select, formerly branded as Omeat, is a Thousand Oaks-based cultivated meat company focused on producing real beef grown from animal cells at industrial scale. The firm aims to integrate its cultivated beef into existing supply chains, offering predictable pricing, consistent quality, and insulation from traditional cattle-market volatility. Its "infrastructure-grade" approach is positioned to work alongside, rather than replace, the conventional beef industry. Evergreen Select’s products are free of antibiotics, GMOs, and other artificially engineered inputs. Management plans to channel newly raised capital into expanding operational capacity and accelerating R&D efforts. To date, the company has secured more than $55 million in total funding. No revenue, user, or production volume figures were disclosed in the article.